1. Medicines
  2. Rheumatology
  3. COSENTYX® (secukinumab)
  4. Why target IL-17A?

Click here for Prescribing Information

Why target IL-17A?

Why target IL-17A?

Image of the IL-17A and Cosentyx molecules

Cosentyx is the first and only fully human targeted IL-17A inhibitor approved for use in PsA and axSpA1

IL-17A is a cornerstone cytokine that plays a critical role at inflammation sites associated with PsA and axSpA indications.2,4

 

 

Arrow with the text: Why Cosentyx in PsA? Click image to find out more

Arrow with the text: Why Cosentyx in axSpA? Click image to find out more

AS, ankylosing spondylitis; axSpA, axial spondyloarthritis; DMARD, disease-modifying antirheumatic drug; IL, interleukin; MRI, magnetic resonance imaging; nr-axSpA, non-radiographic axial spondyloarthritis; NSAID, non-steroidal anti-inflammatory drug; PASI, Psoriasis Area and Severity Index; PsA, psoriatic arthritis; PsO, plaque psoriasis.

  1. Cosentyx (secukinumab) Summary of Product Characteristics. Available at www.medicines.ie. Accessed March 2023.
  2. Patel DD et al. Ann Rheum Dis. 20 13;72 (suppl. 2):ii116 -23.
  3. Kirkham B et al. Immunology. 2013;141:133–42.
  4. Miossec P and Kolls JK. Nat Rev Drug Discov. 2012;11:763–76.
  5. Spindeldreher S et al. Dermatol Ther (Heidelb). 2018;8:57–68.
Rate this content: 
No votes yet
IE271483 | March 2023
Rheumatology
Print

Reporting of side effects
Reporting suspected adverse reactions of the medicinal product is important to Novartis and the HPRA. It allows continued monitoring of the benefit/risk profile of the medicinal product. All suspected adverse reactions should be reported via HPRA Pharmacovigilance, website: www.hpra.ie. Adverse events could also be reported to Novartis preferably via www.report.novartis.com or by email: [email protected] or by calling 01 2080 612.

×

Ask Speakers

×

Medical Information Request